CN104547676A - Traditional Chinese medicinal composition for treating stable-phase bronchiectasis and preparation of composition - Google Patents
Traditional Chinese medicinal composition for treating stable-phase bronchiectasis and preparation of composition Download PDFInfo
- Publication number
- CN104547676A CN104547676A CN201410814567.2A CN201410814567A CN104547676A CN 104547676 A CN104547676 A CN 104547676A CN 201410814567 A CN201410814567 A CN 201410814567A CN 104547676 A CN104547676 A CN 104547676A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- preparation
- composition
- bronchiectasis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a traditional Chinese medicinal composition which has a significant curative effect for stable-phase bronchiectasis. The composition includes the following constituents: ginseng, astragalus membranaceus, schisandra, fruit of Chinese wolfberry, adenophora tetraphylla, radix glehniae, radix ophiopogonis, lily, radix rehmanniae, root bark of white mulberry, cortex lycii radicis, radix salviae miltiorrhizae, fritillaria cirrhosa and bamboo juice. The preparation includes capsules, particles, tablets, pills and oral liquids, and the raw materials for preparing the preparation are readily available. The preparation nourishes yin and generates body fluid, moistens the lung to relieve a cough, fortifies the spleen, reduces phlegm and dissipates dampness. All gather together to provide functions of tonifying qi, strengthening the exterior, invigorating the lung, nourishing yin, fortifying the spleen, reducing phlegm, dissipating dampness, diminishing inflammation, relieving asthma, and promoting blood circulation to remove blood stasis. The composition hits the pathogenesis of stable-phase bronchiectasis and is mainly used for treating stable-phase bronchiectasis.
Description
Technical field
The present invention relates to the treatment bronchiectasic Chinese medicine composition of stable phase and preparation thereof, belong to tcm field
Background technology
Bronchiectasis is the disease caused by the chronic abnormal dilatation of bronchus, belongs to one of respiratory system disease being difficult to effect a radical cure.Due to bronchus and surrounding tissue chronic inflammatory disease thereof and bronchial obstruction, cause the pathological destruction that bronchial tissue's structure is more serious, so that bronchus lumen distention and distortion.Main clinical manifestation is chronic cough, vomicas and repeatedly spit blood.Easy Complicated with Pulmonary abscess, emphysema, pulmonary heart disease.Primary disease is very common in China rural area, disability rate and fatality rate high.Therefore need to take effectively preventing measure to intervene.Current clinical groundwork focuses on treatment bronchiectasis acute exacerbation, and for stable phase patient, how to alleviate clinical symptoms, and reduce acute exacerbation, delay disease progression, improve health status, improve life quality, means are very limited.Comprise smoking cessation, preventing cold, the inoculation of multivalence pneumovax at present and adopt Western medicine medicine to relieving asthma, the remedy measures that eliminates the phlegm all obtains certain effect, but this disease obtains Satisfactory Control not yet, especially in the bronchiectasic treatment of stable phase.Acute exacerbation how is avoided to be vital in the control of this disease.Play the advantage of the traditional Chinese medical science, therapeutic intervention can be carried out to stable phase bronchiectasis, reduce acute exacerbation, improve clinical symptoms.But determined curative effect, effectively can treat the bronchiectasic Chinese medicine preparation of stable phase to lack still very much, the present invention carries out developing, process, develop and obtaining according to the traditional proved recipe in locality, raw material easily obtains, and medicine itself does not have toxic and side effects, more safe and reliable, medicine successful, its production method is simple simultaneously, and Conventional processing methods is used for, in the production of crude drug provided by the invention, can not causing the loss of effective ingredient.
Summary of the invention
The object of the present invention is to provide a kind of therapeutic effect good, have no side effect, the treatment of the determined curative effect treatment bronchiectasic Chinese medicine composition of stable phase and preparation thereof, to overcome the deficiencies in the prior art.
The technical scheme that the present invention solves the problems of the technologies described above is as follows:
One treats the bronchiectasic Chinese medicine composition of stable phase, comprises the raw material of following weight portion:
By Radix Ginseng 3-6 part, Radix Astragali 10-20 part, Fructus Schisandrae Chinensis 10-20 part, Fructus Lycii 10-20 part, Radix Adenophorae 10-20 part, Radix Glehniae 10-20 part, Radix Ophiopogonis 10-20 part, Bulbus Lilii 10-20 part, Radix Rehmanniae 10-20 part, Cortex Mori 10-20 part, Cortex Lycii 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Bulbus Fritillariae Cirrhosae 10-20 part, Succus Bambusae 10-20 part forms.
As technique scheme further preferably, described composite preparation comprises the raw material of following weight portion:
Radix Ginseng 3 parts, the Radix Astragali 10 parts, Fructus Schisandrae Chinensis 10 parts, Fructus Lycii 10 parts, Radix Adenophorae 10 parts, Radix Glehniae 10 parts, Radix Ophiopogonis 10 parts, Bulbus Lilii 10 parts, 10 parts, the Radix Rehmanniae, Cortex Mori 10 parts, Cortex Lycii 10 parts, Radix Salviae Miltiorrhizae 10 parts, Bulbus Fritillariae Cirrhosae 10 parts, Succus Bambusae 20 parts composition.
Preparation of the present invention be Chinese medicine produce in by any dosage form made of prior art, comprise capsule preparations, dissolved granule, tablet, pill or oral liquid formulations.
In technique scheme, each taste Chinese medicine in compositing formula has following effect:
This invention forms primarily of 14 kinds of Chinese medicines, wherein Radix Ginseng, the Radix Astragali, QI invigorating warming YANG, benefiting QI for strengthening the superficies; Fructus Schisandrae Chinensis, Fructus Lycii, YIN nourishing and the production of body fluid promoting of astringing the lung; Radix Adenophorae, Radix Glehniae, Radix Ophiopogonis, Bulbus Lilii, the Radix Rehmanniae, nourishing YIN and moistening the lung; Cortex Mori, Cortex Lycii, Radix Salviae Miltiorrhizae, eliminate the phlegm active; Bulbus Fritillariae Cirrhosae, Succus Bambusae, clearing away lung-heat, eliminate the phlegm.This invention YIN nourishing and the production of body fluid promoting, nourishing the lung to arrest cough, spleen invigorating expectoration removing dampness, full side gathers that benefiting QI for strengthening the superficies, tonifying the lung yin nourishing, spleen invigorating expectoration removing dampness, antiinflammatory are relievingd asthma, the merit of blood circulation promoting and blood stasis dispelling altogether, and hit stable phase bronchiectasis pathogenesis.
The present invention carries out developing, process, develop and obtaining according to the traditional proved recipe in locality, medicine itself does not have toxic and side effects, more safe and reliable, medicine successful, its production method is simple simultaneously, Conventional processing methods is used for, in the production of crude drug provided by the invention, can not causing the loss of effective ingredient; And in this invention preparation, raw material easily obtains.
Traditional medicine thinks that primary disease belongs to the category such as " spitting of blood ", " lung abscess ", " cough " of Chinese medicine.Primary disease pathogenesis is familiar with at present and is trended towards deficiency in origin and excess in superficiality more.How empty prolonged illness is, and immunity of organisms lowly and repeatedly bronchial obstruction is the major reason of repeated infection.So should strengthening the body resistance be paid attention at stable phase, by tonification lung spleen kidney, to improve body's immunity, strengthen and resist exopathogen ability, reduce the chance of recurrent exerbation.Lung, spleen, damage of suffering from a deficiency of the kidney, retention of phlegm and blood stasis in the lung, strongly fragrant heat-transformation of a specified duration, heat stop up blood stasis, pathogens accumulating to form abscess, for the inherent pathogenesis pathological change of primary disease, pathogenic characteristic is deficiency in origin and excess in superficiality, deficiency in origin is suffered from a deficiency of the kidney based on lung spleen, and mark is real in lung-heat, phlegm-damp, blood stasis, and expectorant, the stasis of blood, hot three are the basic reasons of the touching delay of primary disease, recurrent exerbation.This sick stable phase is based on deficiency in origin, and polyphyly lung spleen is suffered from a deficiency of the kidney damage, belongs to lung Pishenqixu syndrome, and has lung-dryness syndrome due to deficiency of YIN.Should consolidate by QI invigorating, yin nourishing spleen invigorating, blood circulation promoting and blood stasis dispelling, the method for antiinflammatory expectoration, to make inside of human body negative and positive of qi and blood balance, function is recovered, and immunologic function improves, thus reduces attack times, improves Nutritional Status of Patients and quality of life.This is dialectical basis of the present invention.The present invention is also the traditional Chinese medical science " radical treatment in chronic case ", " prevention of diseae ", the fully demonstrating of " namely disease is preapred for an unfavorable turn of events " principle.
Owing to have employed technique scheme, the present invention has QI invigorating and consolidates, yin nourishing spleen invigorating, blood circulation promoting and blood stasis dispelling, antiinflammatory expectoration effect.Inventor started to apply technical solutions according to the invention before the several years, and treatment hundreds stable phase bronchiectasis patient, obtains good curative effect.
Detailed description of the invention:
The first: get Radix Ginseng 3g, Radix Astragali 10g, Fructus Schisandrae Chinensis 10g, Fructus Lycii 10g, Radix Adenophorae 10g, Radix Glehniae 10g, Radix Ophiopogonis 10g, Bulbus Lilii 10g, Radix Rehmanniae 10g, Cortex Mori 10g, Cortex Lycii 10g, Radix Salviae Miltiorrhizae 10g, Bulbus Fritillariae Cirrhosae 10g, Succus Bambusae 20g, above-mentioned raw materials medicine is fried into decoction take, every day potion, be divided into and sooner or later take for twice, serve on 30 days.
The second: by weight: Radix Ginseng 3, the Radix Astragali 10, Fructus Schisandrae Chinensis 10, Fructus Lycii 10, Radix Adenophorae 10, Radix Glehniae 10, Radix Ophiopogonis 10, Bulbus Lilii 10, the Radix Rehmanniae 10, Cortex Mori 10, Cortex Lycii 10, Radix Salviae Miltiorrhizae 10, Bulbus Fritillariae Cirrhosae 10, Succus Bambusae 20, by above-mentioned raw materials medicine kilogram to be that unit of weight is fried concentrated, honey is smelt ball.Every ball weighs 0.5 gram, sooner or later respectively takes 6 balls, takes 30 days continuously.
The third: by weight: Radix Ginseng 3, the Radix Astragali 10, Fructus Schisandrae Chinensis 10, Fructus Lycii 10, Radix Adenophorae 10, Radix Glehniae 10, Radix Ophiopogonis 10, Bulbus Lilii 10, the Radix Rehmanniae 10, Cortex Mori 10, Cortex Lycii 10, Radix Salviae Miltiorrhizae 10, Bulbus Fritillariae Cirrhosae 10, Succus Bambusae 20, by above-mentioned raw materials medicine kilogram to be jointly processed into fine powder for unit of weight, cross 100 orders with top sieve, mix homogeneously, ozone sterilization 20 minutes, technique makes capsule routinely, every heavy 0.5 gram, sooner or later respectively take 4-6 grain, warm water delivery service, take 30 days continuously.
4th kind: by weight Radix Ginseng 3, the Radix Astragali 10, Fructus Schisandrae Chinensis 10, Fructus Lycii 10, Radix Adenophorae 10, Radix Glehniae 10, Radix Ophiopogonis 10, Bulbus Lilii 10, the Radix Rehmanniae 10, Cortex Mori 10, Cortex Lycii 10, Radix Salviae Miltiorrhizae 10, Bulbus Fritillariae Cirrhosae 10, Succus Bambusae 20, above-mentioned raw materials medicine is added 500ml water, after being fully mixed into medicinal liquid, medicinal liquid is decocted into cream, is condensed into granule, pack, every bag heavy 3 grams, sooner or later respectively take 1 bag, warm water delivery service, take 30 days continuously.
5th kind: by weight: Radix Ginseng 3, the Radix Astragali 10, Fructus Schisandrae Chinensis 10, Fructus Lycii 10, Radix Adenophorae 10, Radix Glehniae 10, Radix Ophiopogonis 10, Bulbus Lilii 10, the Radix Rehmanniae 10, Cortex Mori 10, Cortex Lycii 10, Radix Salviae Miltiorrhizae 10, Bulbus Fritillariae Cirrhosae 10, Succus Bambusae 20, above-mentioned raw materials medicine is added 1000ml water, after being fully mixed into medicinal liquid, oral liquid processing technology routinely again, medicinal liquid is decocted and is concentrated into 200ml, the oral liquid formulations of the present invention that can make.The instructions of taking of oral liquid: every day twice, each 10-20ml, warm water delivery service, takes 30 days continuously.
6th kind: by weight: Radix Ginseng 3, the Radix Astragali 10, Fructus Schisandrae Chinensis 10, Fructus Lycii 10, Radix Adenophorae 10, Radix Glehniae 10, Radix Ophiopogonis 10, Bulbus Lilii 10, the Radix Rehmanniae 10, Cortex Mori 10, Cortex Lycii 10, Radix Salviae Miltiorrhizae 10, Bulbus Fritillariae Cirrhosae 10, Succus Bambusae 20, by above-mentioned raw materials medicine kilogram to be jointly processed into fine powder for unit of weight, tablet processing technology routinely again, medicated powder is pressed into the tablet of 0.3 gram every, the tablet of the present invention that can make.The instructions of taking of tablet: every day twice, each 3-4 sheet, warm water delivery service, takes 30 days continuously.
Clinical practice:
1 clinical data
Bronchiectasis diagnosis, according to " internal medicine " the 7th edition, is selected stable phase bronchiectasis patient 72 example, is divided into 2 groups at random, invention group group (treatment group) organizes 36 examples, male 23 example, women 13 example, 47 ~ 71 years old age, average 57.4 years old, average course of disease 8.7 years; Simple western medical treatment group (matched group) 36 example, male 22 example, women 14 example; 45 ~ 68 years old age, average 56.2 years old; Average course of disease 9.1 years; Above-mentioned case derives from the patient reaching stable phase year February in October, 2013 to 20143 and leave hospital after my section's hospitalization, and completed treatment is observed, and informed consent.
2 Therapeutic Method
Matched group give western medicine routine treatment as: posture drainage, use the treatments such as expectorant, bronchodilator, lung reconditioning.The same matched group of the above-mentioned western medicine routine treatment for the treatment of group, separately gives side's decoction of the present invention, fried by systematic unity of boiling medicine during clinical application, and 200mL decocted into by every agent medicine, point two bags of packagings, and sooner or later respectively take 1 bag, 30d was 1 course for the treatment of, observing effect after continuous 3 courses for the treatment of.
3 curative effect judging standards
Effective: cough, expectoration, hemoptysis, uncomfortable in chest, feel suffocated, the symptom such as cyanosis disappears substantially, the dry moist rales of two lungs obviously alleviates; Effective: above-mentioned symptom is improved in varying degrees; Invalid: with symptom before treatment without improving or worsening.
4 results
After 3 courses for the treatment of of two groups of patients, effect is as follows:
Effectiveness comparison (x ± s) before and after two groups of treatments
Note: compare P < 0.05 with after treatment of control group.
In a word, use this invention to treat stable phase bronchiectasis, directly for the pathogenesis of primary disease, determined curative effect, toxic and side effects is little, is the effective ways be worthy to be popularized.
Claims (3)
1. treat a stable phase bronchiectasic Chinese medicine composition, its feature is: according to weight proportion: it by Radix Ginseng 3-6 part, Radix Astragali 10-20 part, Fructus Schisandrae Chinensis 10-20 part, Fructus Lycii 10-20 part, Radix Adenophorae 10-20 part, Radix Glehniae 10-20 part, Radix Ophiopogonis 10-20 part, Bulbus Lilii 10-20 part, Radix Rehmanniae 10-20 part, Cortex Mori 10-20 part, Cortex Lycii 10-20 part, Radix Salviae Miltiorrhizae 10-20 part, Bulbus Fritillariae Cirrhosae 10-20 part, Succus Bambusae 10-20 part forms.
2. treat the bronchiectasic Chinese medicine composition of stable phase as claimed in claim 1, its feature is: the optimum ratio of needed raw material medicine is Radix Ginseng 3 parts, the Radix Astragali 10 parts, Fructus Schisandrae Chinensis 10 parts, Fructus Lycii 10 parts, Radix Adenophorae 10 parts, Radix Glehniae 10 parts, Radix Ophiopogonis 10 parts, Bulbus Lilii 10 parts, 10 parts, the Radix Rehmanniae, Cortex Mori 10 parts, Cortex Lycii 10 parts, Radix Salviae Miltiorrhizae 10 parts, Bulbus Fritillariae Cirrhosae 10 parts, Succus Bambusae 20 parts composition.
3. treat the bronchiectasic Chinese medicine preparation of stable phase as claimed in claim 1 or 2, its feature is: described preparation is obtainable preparation during all Chinese medicine is produced, and comprising: capsule, granule, tablet, pill, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410814567.2A CN104547676B (en) | 2014-12-25 | 2014-12-25 | It is a kind of to treat stationary phase bronchiectasic Chinese medicine composition and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410814567.2A CN104547676B (en) | 2014-12-25 | 2014-12-25 | It is a kind of to treat stationary phase bronchiectasic Chinese medicine composition and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104547676A true CN104547676A (en) | 2015-04-29 |
| CN104547676B CN104547676B (en) | 2018-06-26 |
Family
ID=53065447
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410814567.2A Expired - Fee Related CN104547676B (en) | 2014-12-25 | 2014-12-25 | It is a kind of to treat stationary phase bronchiectasic Chinese medicine composition and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104547676B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998066A (en) * | 2015-08-20 | 2015-10-28 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating bronchiectasia in acute infection period |
| CN105012766A (en) * | 2015-08-20 | 2015-11-04 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating bronchiectasis in stable period |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1253810A (en) * | 1999-10-18 | 2000-05-24 | 厉福昌 | Medicine for curing chronic bronchitis and its preparation method |
| CN1569102A (en) * | 2004-04-27 | 2005-01-26 | 孟庆云 | Medicine for treating bronchodilatation |
-
2014
- 2014-12-25 CN CN201410814567.2A patent/CN104547676B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1253810A (en) * | 1999-10-18 | 2000-05-24 | 厉福昌 | Medicine for curing chronic bronchitis and its preparation method |
| CN1569102A (en) * | 2004-04-27 | 2005-01-26 | 孟庆云 | Medicine for treating bronchodilatation |
Non-Patent Citations (1)
| Title |
|---|
| 李学勇: "综合治疗慢性阻塞性肺疾病稳定期呼吸肌疲劳40例", 《中国中医药现代远程教育》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104998066A (en) * | 2015-08-20 | 2015-10-28 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating bronchiectasia in acute infection period |
| CN105012766A (en) * | 2015-08-20 | 2015-11-04 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treating bronchiectasis in stable period |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104547676B (en) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104173937A (en) | Traditional Chinese medicine composition for dispersing stagnated liver qi for promoting bile flow and applications thereof | |
| CN104587298A (en) | Traditional Chinese medicinal composition for treating pulmonary abscess | |
| CN103977314A (en) | Medicinal composition for treating respiratory diseases as well as preparation method and application of medicinal composition | |
| CN104547496A (en) | Traditional Chinese medicine composition for moistening lung to arrest cough and preparation method thereof | |
| CN102274389B (en) | Chinese medicinal composition for treating chronic pharyngitis | |
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN104547676B (en) | It is a kind of to treat stationary phase bronchiectasic Chinese medicine composition and its preparation | |
| CN102772663A (en) | Orally-taken medicine for preventing and treating infantile asthma and preparation method thereof | |
| CN104306793A (en) | Chinese herba preparation for treating lobar pneumonia | |
| CN104435695B (en) | One kind treats stationary phase bronchiectasic Chinese medicine composition and its preparation | |
| CN105327182A (en) | Medicine for treating child pertussis and preparation method thereof | |
| CN103933408A (en) | Traditional Chinese medicinal decoction for treating acute gouty arthritis | |
| CN107625915A (en) | A kind of Hyssopus officinalis ointment and preparation method thereof | |
| CN106334155A (en) | Traditional Chinese medicine composition for treating arterial thyromegaly and preparation method thereof | |
| CN104257875A (en) | Externally-applied traditional Chinese medicine composition for nursing acute mastitis of women | |
| CN104623588B (en) | A kind of Chinese medicine composition for treating stationary phase chronic cor pulmonale | |
| CN105232661A (en) | Traditional Chinese medicine composition for treating mastitis and preparation method thereof | |
| CN105079487A (en) | Traditional Chinese medicine composition for treating heat stranguria | |
| CN105031444A (en) | Traditional Chinese medicinal composition for treating primary tuberculosis | |
| CN106421543B (en) | A kind of Chinese medicine composition and preparation method thereof for treating cough | |
| CN104510835A (en) | Traditional Chinese medicinal formula for treating intestinal tumor | |
| CN104189815A (en) | Traditional Chinese medicine preparation for treating children bronchial asthma | |
| CN103301318B (en) | Traditional Chinese medicine for treating suppurative pneumonia | |
| CN103610902A (en) | Traditional Chinese medicine (TCM) for treating lung dryness due to deficiency of yin | |
| CN102319349A (en) | Chinese medicinal composition for treating pneumonia and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information |
Inventor after: Xu Mei Inventor before: Zou Deqi Inventor before: Liu Huantao Inventor before: Bi Xiumei Inventor before: Sui Yueling Inventor before: Sun Weihua |
|
| CB03 | Change of inventor or designer information | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20180517 Address after: 266701 Li Yuan Street office health center, 383 Renmin Road, Pingdu City, Qingdao, Shandong Applicant after: Xu Mei Address before: 265100 Haiyang City Third People's Hospital, 3 Haihua Road, Haiyang, Yantai, Shandong Applicant before: Zou Deqi |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180626 Termination date: 20181225 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |